<DOC>
	<DOCNO>NCT02538666</DOCNO>
	<brief_summary>In study , patient must already complete first-line chemotherapy treat extensive-stage disease small cell lung cancer . The purpose study show Nivolumab , Nivolumab plus Ipilimumab follow Nivolumab , prolong overall survival progression free survival administer consolidation treatment patient stable respond chemotherapy . Patients receive treatment compare patient take placebo .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Nivolumab , Nivolumab Combination With Ipilimumab , Placebo Patients With Extensive-Stage Disease Small Cell Lung Cancer ( ED-SCLC ) After Completion Platinum-based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects histologically cytologically confirm extensive stage disease SCLC Ongoing response stable disease well follow 4 cycle platinumbased first line chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Subjects symptomatic Central Nervous System ( CNS ) metastases Subjects receive consolidative chest radiation Subjects active , know , suspect autoimmune disease exclude All side effect attribute prior anticancer therapy must resolve Grade 1 baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>